1. A potential novel biomarker: comprehensive analysis of prognostic value and immune implication of CES3 in colonic adenocarcinoma.
- Author
-
He, Lulu, Zhao, Chenyi, Xu, Jingjing, Li, Wenjing, Lu, Yujie, Gong, Yang, Gu, Dingyi, Wang, Xiaoyan, and Guo, Feng
- Subjects
- *
PROGNOSIS , *GENE expression , *BIOMARKERS , *INTESTINAL tumors , *COLON cancer - Abstract
Purpose: Colon cancer is the most common malignant tumor in the intestine. Abnormal Carboxylesterases 3 (CES3) expression had been reported to be correlated to multiple tumor progression. However, the association among CES3 expression and prognostic value and immune effects in colonic adenocarcinoma (COAD) were unclear. Patients and methods: The transcription and expression data of CES3 and corresponding clinical information was downloaded from The Cancer Genome Atlas (TCGA). The CES3 protein expression and the prognostic value were verified based on tissue microarray data. The Cancer immune group Atlas (TCIA), Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and the GSE78220 immunotherapy cohort were used to forecast immunotherapy efficacy. Finally, a prognostic immune signature was constructed and verified. Results: Compared with normal colon tissues, the expression of mRNA and protein levels of CES3 were downregulated in tumor tissues. CES3 expression was associated with TIICs. Hihg-CES3 COAD patients had better efficacy of concurrent immunotherapy. CES3-related immune genes (CRIs) were identified and were then used to construct prognostic immune signature and had been successfully verified in GES39582. Conclusion: CES3 might be a potential immune-related gene and promising prognostic biomarker in COAD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF